Applied Dna Sciences INC 8-K filings

Applied DNA Sciences replaces Marcum LLP with CBIZ CPAs P.C. as its independent auditor due to CBIZ's acquisition of Marcum's attest business.

Applied DNA Sciences' special meeting of stockholders was adjourned due to the absence of a quorum, impacting the approval of warrant exercises related to a previous offering.

Applied DNA Sciences is shifting its focus to its LineaRx platform, targeting high-margin opportunities in genetic medicine and diagnostics.

Applied DNA Sciences is restructuring to focus on genetic medicine manufacturing, divesting its CertainT platform, and implementing leadership changes, while reporting mixed financial results for fiscal year 2024.

Applied DNA Sciences has received a notice from Nasdaq for failing to maintain the minimum bid price of $1.00 per share, putting its listing at risk.

Applied DNA Sciences has amended its bylaws to reduce the quorum requirement for stockholder meetings and grant the CEO authority to adjourn meetings.

Applied DNA Sciences has announced a $6.5 million registered direct offering and concurrent private placement to fund therapeutic DNA production and general corporate purposes.

Applied DNA Sciences' stockholders approved the election of six directors, ratified the appointment of Marcum LLP as auditor, authorized a reverse stock split, and approved the exercisability of certain warrants at their annual meeting on September 30, 2024.

Applied DNA Sciences has regained compliance with Nasdaq's minimum bid price requirement after its stock price closed above $1.00 for 20 consecutive business days.

Applied DNA Sciences reported its third quarter fiscal year 2024 financial results, showcasing progress in its therapeutic DNA, molecular diagnostics, and DNA tagging segments, despite a revenue decrease due to the conclusion of a COVID-19 testing contract.

Applied DNA Sciences' special stockholder meeting failed to reach a quorum, delaying the approval needed for warrant exercises.

Applied DNA Sciences has received a notice from Nasdaq for not meeting the minimum bid price requirement, putting its listing at risk.

Applied DNA Sciences has received confirmation from Nasdaq that it meets the minimum stockholders' equity requirement, avoiding potential delisting.

Applied DNA Sciences believes it has regained compliance with Nasdaq's minimum stockholders' equity requirement following a recent $10.8 million capital raise.

Applied DNA Sciences has announced the pricing of a public offering expected to generate approximately $12 million in gross proceeds.

Applied DNA Sciences has received a notice from Nasdaq for failing to meet the minimum stockholders' equity requirement, placing its listing status at risk.

Applied DNA Sciences' second quarter fiscal 2024 revenue decreased significantly due to the conclusion of a major COVID-19 testing contract, despite some growth in product revenue.

Applied DNA Sciences is positioning itself to capitalize on the growing genetic medicine market with its PCR-based DNA manufacturing technology and upcoming GMP facility.

Applied DNA Sciences has announced a 1-for-20 reverse stock split, effective April 25, 2024, and updated the CUSIP number for its common stock.

Applied DNA Sciences will implement a 1-for-20 reverse stock split effective April 25, 2024, to regain compliance with Nasdaq's minimum bid price requirement.

Applied DNA Sciences has amended outstanding warrants, reducing the exercise price to $0.609 and extending the expiration date to August 9, 2028.

Applied DNA Sciences' stockholders approved several key proposals at a special meeting, including warrant issuances, repricing, a reverse stock split authorization, and an increase in the equity incentive plan.

Applied DNA Sciences announced its first quarter fiscal 2024 financial results, highlighting progress in its Linea IVT platform and plans for GMP production of mRNA starting materials.

Applied DNA Sciences has entered into agreements for a $3.44 million registered direct offering of common stock and warrants.

Applied DNA Sciences has terminated its equity distribution agreement with Maxim Group, effective January 30, 2024, after selling 90,027 shares.